@Longroaderstar Longroader

Longroader posts on X about $vtyx, $arwr, $prqr, $iova the most. They currently have [---------] followers and [---] posts still getting attention that total [------] engagements in the last [--] hours.

Engagements: [------] #

[--] Week [---------] +981%
[--] Month [---------] +19,161%
[--] Months [---------] +11,853%
[--] Year [---------] +5,322%

Mentions: [--] #

[--] Week [--] -4%
[--] Month [--] +6.30%
[--] Months [---] +269%
[--] Year [---] +107%

Followers: [---------] #

[--] Week [---] +0.89%
[--] Month [---] +4.20%
[--] Months [---] +60%
[--] Year [---] +128%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 44.63% finance 27.27% countries 9.09% cryptocurrencies 3.31%

Social topic influence $vtyx #7, $arwr 12.4%, $prqr 11.57%, $iova #35, $xbi 10.74%, $lly #101, in the 7.44%, $sgmo 7.44%, sanofi 7.44%, $mgx 6.61%

Top accounts mentioned or mentioned by @rnaianalyst @proqr @drmakaryfda @seedy19tron @bioboyscout @yaireinhorn @igisci @nightowlbiotech @applehelix @jfais20 @biotechscanner @biotechiq @sonichedgefund @valueforall1 @ihatewabbitstoo @pawcio2009 @jamesmclaw70633 @avidresearch @bosstrading0 @aggregategains

Top assets mentioned Ventyx Biosciences, Inc. (VTYX) Arrowhead Research Corporation (ARWR) Iovance Biotherapeutics, Inc. Common Stock (IOVA) Eli Lilly and Company (LLY) Sanofi (SNY) Metagenomi Technologies, LLC (MGX) Wave Life Sciences Ltd. Ordinary Shares (WVE) Abivax SA (ABVX) Synthetify (SNY) GSK plc (GSK) Tourmaline Bio, Inc. (TRML) Novo-Nordisk (NVO) Pfizer, Inc. (PFE) Novartis AG (NVS) Day One Biopharmaceuticals, Inc. (DAWN) Viking Therapeutics, Inc (VKTX) Cidara Therapeutics, Inc. (CDTX) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Poseida Therapeutics, Inc. (PSTX) BioAge Labs, Inc. (BIOA) Vir Biotechnology, Inc. Common Stock (VIR) Bitcoin (BTC) Metsera, Inc. (MTSR) Alnylam Pharmaceuticals, Inc. (ALNY)

Top Social Posts

Top posts by engagements in the last [--] hours

"@NightOwlBiotech $VTYX Already acquired by Lily"
X Link 2026-02-03T06:13Z [---] followers, [---] engagements

"@RNAiAnalyst @AppleHelix Actually $sny lost [--] deals first $vtyx and then now maybe $abvx both to $lly. That's a hard pill to swallow"
X Link 2026-02-13T00:54Z [---] followers, [----] engagements

"$prqr Van Herk adding 1.055m shares in Sept for $2.3m. Now holds 13.6%. Keep buying and soon they will own more than Lily"
X Link 2025-10-02T02:06Z [---] followers, [---] engagements

"$dawn Add more to my stash at this level. At$1.3b market cap still cheap. Just in case some BP decide to drop cash this weekend. $dawn Post #JPM2026 runs can only mean one thing. Increased revenues for lead drug in pLGG new ADCs going clinical $450m cash. Potential candidate after $rapt $dawn Post #JPM2026 runs can only mean one thing. Increased revenues for lead drug in pLGG new ADCs going clinical $450m cash. Potential candidate after $rapt"
X Link 2026-01-21T15:03Z [---] followers, [---] engagements

"$vtyx Wow. $SNY sleepwalk through the year-end holidays and allowed $LLY to snag a fantastic deal for VTX-3232. And now the market is rooting for Party A https://www.sec.gov/Archives/edgar/data/1851194/000119312526019700/d93324dprem14a.htm https://www.sec.gov/Archives/edgar/data/1851194/000119312526019700/d93324dprem14a.htm"
X Link 2026-01-23T15:19Z [---] followers, [---] engagements

"$IOVA 1/ Is Iovance the next Kite Pharma It could be ripe for buyout at a time when Big Pharma faces patent cliff and needs to replace best sellers like Keytruda"
X Link 2026-02-03T11:14Z [---] followers, [---] engagements

"$IOVA 5/ TIL cell therapy could be for solid tumors what CAR-T is for blood cancers. Both are better treatments compared to chemo"
X Link 2026-02-03T11:14Z [---] followers, [---] engagements

"$IOVA 6/ Largest shareholder Wayne Rothbaum 28m stock 7.2% stake. Known for concentrated bets. Likely to monetise when the time and price is right - recall pharmacyclics and acerta. Risk reward here is worth a bet. Do your own risk management. Not financial advice"
X Link 2026-02-03T11:14Z [---] followers, [---] engagements

"$prqr @ProQR What is the company waiting for Flee the Netherlands and come to the embrace of Lily. 💥BREAKING: 36% unrealized gains tax just passed in the Dutch House of Representatives. https://t.co/KxMSBUd1qe 💥BREAKING: 36% unrealized gains tax just passed in the Dutch House of Representatives. https://t.co/KxMSBUd1qe"
X Link 2026-02-13T01:00Z [---] followers, [---] engagements

"$xbi #xbi We need fresh leadership. The talkshow clowns don't inspire innovation science and capital. Commissioner @DrMakaryFDA must testify before the Health subcommittee on his terrible leadership of the Food & Drug Administration. Trust in safety & efficacy standards is collapsing. https://t.co/z4oil4elir Commissioner @DrMakaryFDA must testify before the Health subcommittee on his terrible leadership of the Food & Drug Administration. Trust in safety & efficacy standards is collapsing. https://t.co/z4oil4elir"
X Link 2026-02-13T01:03Z [---] followers, [---] engagements

"$sgmo Seems like the binary moment has come again is Sangamo going to produce another rabbit to survive the next quarter Nice swings for the traders. Note they have lots of promise but maybe BP playing hard ball. A venture stake for risk management is prudent here"
X Link 2026-01-29T14:46Z [---] followers, [----] engagements

"$sgmo No news up 25% shorts squeezed $sgmo Seems like the binary moment has come again is Sangamo going to produce another rabbit to survive the next quarter Nice swings for the traders. Note they have lots of promise but maybe BP playing hard ball. A venture stake for risk management is prudent here. $sgmo Seems like the binary moment has come again is Sangamo going to produce another rabbit to survive the next quarter Nice swings for the traders. Note they have lots of promise but maybe BP playing hard ball. A venture stake for risk management is prudent here"
X Link 2026-01-29T15:02Z [---] followers, [----] engagements

"$lly $nvo $vktx $pfe Brutal price wars for GLP-1.resume losing fats muscle and stock price. https://finance.yahoo.com/news/novo-nordisk-shares-plunge-amid-174945795.html https://finance.yahoo.com/news/novo-nordisk-shares-plunge-amid-174945795.html"
X Link 2026-02-04T09:03Z [---] followers, [---] engagements

"$IOVA Nice pull back. Less than [--] weeks to probably the most impt quarter in the history of the company. 4Q revenue [----] guidance IOV-4001 IOV-END-201"
X Link 2026-02-05T16:03Z [---] followers, [---] engagements

"$mgx Nice strength in sea of red today. Of course. Cash is more than 2x mkt cap"
X Link 2026-02-05T16:10Z [---] followers, [---] engagements

"@jfais20 The price was thumbed below $1.8 in Nov [--] before 3rd qtr released. Guess we know who. $iova"
X Link 2026-02-06T00:39Z [---] followers, [---] engagements

"$xbi #xbi Wall Street favorite trades.biotech is not one of them"
X Link 2026-02-06T01:28Z [---] followers, [---] engagements

"@BIOTECHSCANNER Amtagvi is 1st generation. I think the whole franchise is geared towards building 2nd and 3rd gen TIL. $IOVA $LLY just spent $2.4b for Orna with no approved drug yet Ph1/2"
X Link 2026-02-10T02:35Z [---] followers, [---] engagements

"$QNCX Can $MGX do the same Trading embarrassingly way below its cash. https://www.businesswire.com/news/home/20260209949613/en/Quince-Therapeutics-Engages-LifeSci-Capital-as-its-Exclusive-Financial-Advisor-to-Explore-Strategic-Alternatives https://www.businesswire.com/news/home/20260209949613/en/Quince-Therapeutics-Engages-LifeSci-Capital-as-its-Exclusive-Financial-Advisor-to-Explore-Strategic-Alternatives"
X Link 2026-02-10T14:03Z [---] followers, [---] engagements

"$prqr @ProQR Smart people and great companies will leave. The Netherlands is about to commit financial self-destruction. Their parliament just passed a 36% tax on unrealized gains for investments. This will cause wealthy people to move to another tax jurisdiction. People will avoid launching a new business. Stock market investing will https://t.co/QM6XWX1KDi The Netherlands is about to commit financial self-destruction. Their parliament just passed a 36% tax on unrealized gains for investments. This will cause wealthy people to move to another tax jurisdiction. People will avoid launching a"
X Link 2026-02-13T01:18Z [---] followers, [---] engagements

"$mreo Doubled my small stake hovering around $2 and upside is significant with huge unmet need. CMO gave off good vibes at Citi recently"
X Link 2025-12-06T01:55Z [---] followers, [---] engagements

"@_Biotech_iQ $vtyx Great table. [---] can indeed go head to head with [---]. If they can secure a partner and bring this forward the valuation gap is huge. CEO did hint they also have 'other assets' to bring forward in Piper sharing. And [----] should decided in about a month. #jpm26"
X Link 2025-12-08T02:32Z [---] followers, [---] engagements

"$wve $arwr Next-gen obesity RNAi targeting INHBE huge readout today for Wave and in Jan [--] for Arrowhead. Expectations of GLP1-like fast weight loss is low main focus is on muscle loss and others. https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announce-interim-data-phase-1-inlight-trial https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announce-interim-data-phase-1-inlight-trial"
X Link 2025-12-08T09:42Z [---] followers, [----] engagements

"$wve $arwr Hold on to your stocks 🚀 Once or twice yearly dosing Lean mass preserved Similar fat loss as GLP1 Safe Wave is now a very attractive buyout target. $GSK"
X Link 2025-12-08T13:56Z [---] followers, [---] engagements

"$wve $gsk $pfe bought the wrong company once again $10b $mtsr"
X Link 2025-12-08T13:57Z [---] followers, [---] engagements

"@RNAiAnalyst $wve They should. Like Cidara. Raising cash will strengthen their hand if any BP pursues them. $10b Metsera"
X Link 2025-12-08T16:42Z [---] followers, [---] engagements

"$WVE Pricing $19 $350m. Strong demand"
X Link 2025-12-10T07:23Z [---] followers, [---] engagements

"$WVE Reclaim back 20s some big boys didnt get their allocations. All eyes on #JPM26 next. $WVE Pricing $19 $350m. Strong demand. $WVE Pricing $19 $350m. Strong demand"
X Link 2025-12-10T16:25Z [---] followers, [---] engagements

"@seedy19tron $cdtx $abvx It is also instructive to study the price chart history in from 24Oct to 13Nov. Could have bought on some days below [---]. The rest is history"
X Link 2025-12-13T04:33Z [---] followers, [----] engagements

"@BioBoyScout @sonichedgefund @RNAiAnalyst $prqr A new partnership with $ALNY would be a good strategic diversification from $LLY"
X Link 2025-12-13T05:27Z [---] followers, [---] engagements

"$xbi #xbi Price can be a proxy indicator of feverish bidding for prized assets but dont let it fool you on the intrinsic value of the asset. In case of $cdtx it was trading in the low $100s before being taken out at $218. Expect the same for $vtyx @seedy19tron $cdtx $abvx It is also instructive to study the price chart history in from 24Oct to 13Nov. Could have bought on some days below [---]. The rest is history. https://t.co/S1VCISmsX5 @seedy19tron $cdtx $abvx It is also instructive to study the price chart history in from 24Oct to 13Nov. Could have bought on some days below [---]. The rest is"
X Link 2025-12-15T09:36Z [---] followers, [---] engagements

"$ARWR As we head into #JPM26 stock price could hit $100 weeks ahead. No reason to trade below $IONS market cap with such an incredible platform and pipeline"
X Link 2025-12-22T23:00Z [---] followers, [----] engagements

"$arwr Jan [--] and Jan [--]. Buckle up. Arrowhead Pharmaceuticals plans to participate in investor conferences and events in January [----]. Additional details can be found here: https://t.co/pQdLy65cZW https://t.co/f182oXr7Ks Arrowhead Pharmaceuticals plans to participate in investor conferences and events in January [----]. Additional details can be found here: https://t.co/pQdLy65cZW https://t.co/f182oXr7Ks"
X Link 2025-12-23T12:38Z [---] followers, [---] engagements

"$SNY $VTYX CRL for BTK inhibitor for neuroinflammation. Sanofi needs new tools even more now. https://www.globenewswire.com/news-release/2025/12/24/3210238/0/en/Press-Release-Sanofi-provides-update-on-tolebrutinib-regulatory-submission-in-non-relapsing-secondary-progressive-multiple-sclerosis.html_gl=1*1eywivr*_up*MQ.*_ga*OTk3NDA4MzY4LjE3NjY1NjYyODk.*_ga_ERWPGTJ5X8*czE3NjY1NjYyODkkbzEkZzAkdDE3NjY1NjYzMDUkajQ0JGwwJGgw"
X Link 2025-12-24T09:33Z [---] followers, [---] engagements

"$SNY $DVAX $VTYX Next should be Ventyx. https://investors.dynavax.com/news-releases/news-release-details/sanofi-acquire-dynavax-adding-marketed-adult-hepatitis-b-vaccine https://investors.dynavax.com/news-releases/news-release-details/sanofi-acquire-dynavax-adding-marketed-adult-hepatitis-b-vaccine"
X Link 2025-12-24T09:37Z [---] followers, [---] engagements

"$SNY $DVAX $LLY $ABVX $VTYX Cross fertilization happening in progress. Thats why Trump and Macron keeps it strong. Sanofi buys Dynavax soon Lily buys Abivax and Sanofi buys Ventyx.it goes on. $SNY $DVAX $VTYX Next should be Ventyx. https://t.co/Emqe6a1R08 $SNY $DVAX $VTYX Next should be Ventyx. https://t.co/Emqe6a1R08"
X Link 2025-12-25T00:50Z [---] followers, [---] engagements

"@ValueForAll1 @RNAiAnalyst @IHateWabbitsToo $prqr Cohort [--] to [--] for AX-0810 is four weeks dosing followed by [--] weeks follow up. Will be surprised if next week for Cohort [--] likely mid-Jan. If target engagement is established will be well worth the wait"
X Link 2025-12-28T04:17Z [---] followers, [---] engagements

"$mreo $rare There was a small signal in fracture reduction for younger patients but alas not statistically significant. Disappointing although only a small bet. Signs were there at the interim. https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-phase-3-orbit-and-cosmic-results-setrusumab https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-phase-3-orbit-and-cosmic-results-setrusumab"
X Link 2025-12-29T14:30Z [---] followers, [---] engagements

"$abvx Strange timing. Why would ABVX discuss this publicly if they are in negotiations Unless deal is reached or no deal. Hope for the former. BOOM💥Marc to discuss M&A info publicly. $ABVX CEO Marc along with top sell-side advisor Centerview will attend an M&A-related webinar on Jan [--]. Topics: M&A dynamics ahead of #JPM26; cross-border M&A under new US tariff rules; and how to approach BPs for a deal. Link👇 https://t.co/ME3eKey568 BOOM💥Marc to discuss M&A info publicly. $ABVX CEO Marc along with top sell-side advisor Centerview will attend an M&A-related webinar on Jan [--]. Topics: M&A"
X Link 2025-12-30T09:03Z [---] followers, [----] engagements

"$xbi #xbi ".were now entering an expansion part of the cycle." Hear it from the veteran. Sputtering Zero chances. Im empathetic to the personal stories but dont think these anecdotes reflect the reality on the ground. Im feeling more positive now than in years. Biotech is a cyclic business. We had a bubble of overbuilding overhiring and overfunding https://t.co/e0Lx6bGcp2 Sputtering Zero chances. Im empathetic to the personal stories but dont think these anecdotes reflect the reality on the ground. Im feeling more positive now than in years. Biotech is a cyclic business. We had a bubble of"
X Link 2025-12-31T11:15Z [---] followers, [---] engagements

"@pawcio2009 @seedy19tron Great pick. Enjoy the gains further in 2026"
X Link 2026-01-01T02:53Z [---] followers, [---] engagements

"$arwr Can someone confirm if they are in Grand Ballroom Thats the hundred billion market cap group. While this schedule is preliminary $ARWR announced today they will be presenting at #JPM26 on 1/12 at 10:30am. Which would put them in the grand ballroom right after the $PFE presentation. You dont get that spot unless you have something interesting to say. ALK7 INHBE While this schedule is preliminary $ARWR announced today they will be presenting at #JPM26 on 1/12 at 10:30am. Which would put them in the grand ballroom right after the $PFE presentation. You dont get that spot unless you have"
X Link 2026-01-05T03:13Z [---] followers, [----] engagements

"$xbi #xbi Nice rug pull for #JPM26 attendees to add before the biofest next week. Need a wave of buyouts to start the fever"
X Link 2026-01-05T15:05Z [---] followers, [---] engagements

"$nvo $lly $wve $arwr The weight loss war has descended into a price war. You cannot win without a differentiated product. INHBE and ALK7 silencing is grounded in human genetics and has the potential to work alongside GLP-1 agonists. Novo $NVO has launched oral Wegovy in the U.S. the first daily GLP-1 pill cleared for obesity. Self-pay starts at $149/mo (1.5mg 4mg) and $299/mo (9mg 25mg) vs $349/mo for the lowest-dose injectable. With commercial insurance copays can be as low as $25. $LLY https://t.co/m3KMCDtg40 Novo $NVO has launched oral Wegovy in the U.S. the first daily GLP-1 pill cleared"
X Link 2026-01-06T02:56Z [---] followers, [---] engagements

"@BioBoyScout @JamesMclaw70633 Hope they breakdown fat and muscle. That's the golden pop to [---]. $arwr"
X Link 2026-01-06T03:01Z [---] followers, [---] engagements

"@RNAiAnalyst @avidresearch $arwr INHBE data could have released before $wve. Considering preclinical kd it should not differ v much. Why they chose to do same time as ALK7. They must have seen 2)"
X Link 2026-01-06T03:19Z [---] followers, [---] engagements

"$arwr Amazing results exceeded my expectations. Better than tirzepatide alone and helps diabetes patients further. Now KOL session next. Bring it to 100"
X Link 2026-01-06T14:01Z [---] followers, [---] engagements

"$xbi #xbi #JPM26 rally begins today. Let the buyouts begin"
X Link 2026-01-06T14:16Z [---] followers, [---] engagements

"$VTYX WSJ for over $1b.make it at least $1.5b to match Tourmaline. Wait for official PR before the celebration begins. 🥂 Good for #xbi $xbi $VTYX Pull back into 7s together with #xbi high volume 10s options activity for Mar. On-going negotiations with Sanofi and/or others. $550m mkt cap only. $trml was bought by Novartis for $1.4b. $VTYX Pull back into 7s together with #xbi high volume 10s options activity for Mar. On-going negotiations with Sanofi and/or others. $550m mkt cap only. $trml was bought by Novartis for $1.4b"
X Link 2026-01-06T23:48Z [---] followers, [---] engagements

"$ARWR Good move to raise cash now. They will only get stronger. INHBE and ALK7 great potential to be partnered too. #JPM26"
X Link 2026-01-07T23:43Z [---] followers, [---] engagements

"$VTYX $1.2b is decent although more would have been great. Remember this was below $200m for the longest time last year. My lowest entry printed at $1.03. Great for #xbi . 1st buyout of the year. Cheers 🥂 $VTYX $14 per share $1.2b https://t.co/aQ9PWDX5gM $VTYX $14 per share $1.2b https://t.co/aQ9PWDX5gM"
X Link 2026-01-08T01:14Z [---] followers, [---] engagements

"$prqr AX-0810 - No safety signals Cohort [--] (impt) - Phase [--] data 1H26 New development candidates selected: AX-2402 (Rett) and AX-2911 (MASH). Interesting 80% reduction in hepatic fat content mouse model. https://www.proqr.com/press-releases/proqr-announces-encouraging-ax-0810-phase-1-safety-and-pk-data-development-candidate-selections-and-2026-outlookutm_source=Newsletter&utm_medium=email&utm_campaign=PR_emailalerts"
X Link 2026-01-08T16:47Z [---] followers, [---] engagements

"$prqr 1H Data for AX-0810 will be one of the most important in the company history: - RNA editing levels - target engagement data - Axiomer platform validation - fund-raising They will get it all out to capture the Street. MASH was a teaser to snag another partnership"
X Link 2026-01-09T16:59Z [---] followers, [---] engagements

"$prqr Cohorts [--] to [--] higher doses more meaningful results. Still expectations were high for [--] data drop. Predict fireworks at AGM in June. Will $LLY take them out before Cash is till mid-27 but they should raise mid-26. $prqr 1H Data for AX-0810 will be one of the most important in the company history: - RNA editing levels - target engagement data - Axiomer platform validation - fund-raising They will get it all out to capture the Street. MASH was a teaser to snag another partnership. $prqr 1H Data for AX-0810 will be one of the most important in the company history: - RNA editing levels -"
X Link 2026-01-10T07:40Z [---] followers, [---] engagements

"$prqr Now $184m market cap still one of the most promising candidate in RNA editing $3b $LLY partnership and very interesting pipeline fully owned IP. It's a big risk for sure. Manage your own risk and trades. I will still maintain a sizeable venture block"
X Link 2026-01-10T07:48Z [---] followers, [---] engagements

"$ABVX $LLY The two CEOs are at #JPM26 right So.a cup of coffee together would be nice. Keep your eyes open at the cafe"
X Link 2026-01-12T15:32Z [---] followers, [---] engagements

"@BioBoyScout $arwr Now the negotiations can happen with a stronger hand. Strategic timing. Key obesity players $lly and $nvo will need to extend their GLP-1 franchise"
X Link 2026-01-12T23:45Z [---] followers, [---] engagements

"#xbi $xbi Time to move on.but still think rest of the year is very positive for deals. [--] big tailwinds - interest rate $170b patent cliff. https://www.fiercebiotech.com/biotech/all-meetings-none-mega-deals-jpms-purpose-evolving https://www.fiercebiotech.com/biotech/all-meetings-none-mega-deals-jpms-purpose-evolving"
X Link 2026-01-19T03:02Z [---] followers, [---] engagements

"$AVRO $FRLN Gaucher cousins maybe diff fate. Freeline burned through its cash. https://www.globenewswire.com/news-release/2023/11/22/2784727/0/en/Syncona-to-Acquire-Freeline-Therapeutics.html https://www.globenewswire.com/news-release/2023/11/22/2784727/0/en/Syncona-to-Acquire-Freeline-Therapeutics.html"
X Link 2023-11-22T14:22Z [---] followers, [---] engagements

"$IPSC $ARVN #xbi Few deals today looking hopeful for more over the weekend as stubborn rates push factor perhaps. https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-strengthens-position-autoimmune-disease https://www.streetinsider.com/dr/news.phpid=23054154 https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-strengthens-position-autoimmune-disease https://www.streetinsider.com/dr/news.phpid=23054154"
X Link 2024-04-11T13:23Z [---] followers, [---] engagements

"$lbph #xbi Curse is lifted. Gonna rain a lot more deals. https://www.businesswire.com/news/home/20241013952344/en/Lundbeck-to-Acquire-Longboard-Pharmaceuticals-in-a-Strategic-Deal-Significantly-Enhancing-Its-Neuroscience-Pipeline https://www.businesswire.com/news/home/20241013952344/en/Lundbeck-to-Acquire-Longboard-Pharmaceuticals-in-a-Strategic-Deal-Significantly-Enhancing-Its-Neuroscience-Pipeline"
X Link 2024-10-14T11:03Z [---] followers, [--] engagements

"#xbi $xbi $pstx Wow keep it flowing. $1.5b. Roche has seen enough to acquire the whole outfit. Was a [----] partnership $110m upfront $6b aggregate deal. https://investors.poseida.com/news-releases/news-release-details/poseida-therapeutics-inc-announces-agreement-be-acquired-roche https://investors.poseida.com/news-releases/news-release-details/poseida-therapeutics-inc-announces-agreement-be-acquired-roche"
X Link 2024-11-26T08:10Z [---] followers, [----] engagements

"$SGMO $PSTX Takeda abandons Poseida Astellas courted and Roche buyout. Connect the dots for Sangamo"
X Link 2025-01-05T12:26Z [---] followers, [----] engagements

"$VTYX $SNY A reminder Sanofi also made an equity investment into Ventyx at $3.8 per share. https://www.globenewswire.com/news-release/2025/05/21/3086232/0/en/Press-Release-Sanofi-to-acquire-Vigil-Neuroscience-Inc-adding-a-new-investigational-medicine-to-treat-Alzheimer-s-disease-to-the-neurology-pipeline.html https://www.globenewswire.com/news-release/2025/05/21/3086232/0/en/Press-Release-Sanofi-to-acquire-Vigil-Neuroscience-Inc-adding-a-new-investigational-medicine-to-treat-Alzheimer-s-disease-to-the-neurology-pipeline.html"
X Link 2025-05-22T02:23Z [---] followers, [----] engagements

"$trml $xbi #xbi Novartis busy reinvesting pipeline - Anthos Argo $rgls $arwr and now Tourmaline. https://www.bloomberg.com/news/articles/2025-09-09/novartis-agrees-to-buy-tourmaline-bio-for-48-per-share-in-cash-mfc3mnvwtaid=68bfbd6e97ba3000013f7c9c&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter https://www.bloomberg.com/news/articles/2025-09-09/novartis-agrees-to-buy-tourmaline-bio-for-48-per-share-in-cash-mfc3mnvwtaid=68bfbd6e97ba3000013f7c9c&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter"
X Link 2025-09-09T07:59Z [---] followers, [---] engagements

"$SPRB $SGMO Very similar profiles BLA 1Q [----] under accelerated approval path low cash runway rare disease focus. Key diff is Sangamo has better IP and multiple pathways to success. Huge boost in confidence for this space. https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-receives-us-fda-breakthrough-therapy https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-receives-us-fda-breakthrough-therapy"
X Link 2025-10-07T02:06Z [---] followers, [----] engagements

"$prme $ntla $mgx $beam $edit $crsp $sgmo $srpt Next gene editing. *TRUMP ADMIN IN TALKS FOR STAKES IN QUANTUM-COMPUTING COS:WSJ *TRUMP ADMIN IN TALKS FOR STAKES IN QUANTUM-COMPUTING COS:WSJ"
X Link 2025-10-23T10:43Z [---] followers, [---] engagements

"$VTYX Moving past the previous high mark easily now at mc $525m cash approx $200m. RP alone suffice at least double the current market cap. 40k patients in USA [----] Arcalyst sales $417m and growing. Market opportunity is huge"
X Link 2025-10-30T13:47Z [---] followers, [---] engagements

"$VTYX $18 target puts Ventyx at $1.3b close to $trml buyout. That's just VTX-3232 alone. If they also hit the mark with VTX-2735 it should cross $20. $VTYX H.C. Wainwright upgraded Ventyx Biosciences to Buy from Neutral with an $18 price target. The firm says the recent acquisition from Novartis of Tourmaline highlights hsCRP biomarker for cardiovascular disease. Recent data from Ventyx's VTX3232 Phase [--] trial for obesity and $VTYX H.C. Wainwright upgraded Ventyx Biosciences to Buy from Neutral with an $18 price target. The firm says the recent acquisition from Novartis of Tourmaline"
X Link 2025-11-05T14:18Z [---] followers, [---] engagements

"$vtyx 1/ The global ASCVD reached a value of $24b in [----] in particular colchicine sales estimated at $1.58b. GLP-1 agonists plus an orthogonal drug like VTX-3232 will become the SOC for ASCVD very soon. Safe effective oral and less side effects"
X Link 2025-11-06T15:15Z [---] followers, [---] engagements

"$vtyx 2/ Norvatis paid $1.4b for tourmaline bio too early. Sanofi now has a shot to overtake them with VTX3232 - oral faster rapid drop in hsCRP and lower infection risk"
X Link 2025-11-06T15:15Z [---] followers, [---] engagements

"$vtyx At $10 Ventyx is now $707m mcap and $500m EV. For VTX3232 a move by Sanofi for Parkinson's should be around this valuation similar to Vigil"
X Link 2025-11-25T14:42Z [---] followers, [---] engagements

"@yaireinhorn @igisci @RNAiAnalyst $mgx Metagenomi should liquidate and return cash to stockholders. More than $4 can be realised. Soleus or Tang can pressure them like Essa"
X Link 2025-11-25T15:50Z [---] followers, [---] engagements

"$MGX Cardiometabolic target revealed for IONIS. APOC3 https://ir.metagenomi.co/news-releases/news-release-details/metagenomi-present-preclinical-data-supporting-new-collaboration https://ir.metagenomi.co/news-releases/news-release-details/metagenomi-present-preclinical-data-supporting-new-collaboration"
X Link 2025-12-01T14:29Z [---] followers, [---] engagements

"$prqr Could use a voucher here for Rett syndrome. https://www.fiercepharma.com/pharma/house-endorses-bill-would-revive-fdas-rare-pediatric-review-voucher-program https://www.fiercepharma.com/pharma/house-endorses-bill-would-revive-fdas-rare-pediatric-review-voucher-program"
X Link 2025-12-03T08:39Z [---] followers, [---] engagements

"$bioa $vtyx Nice results but we already expected this from Ventyx findings. Expansion will just validate hsCRP drop as well. https://ir.bioagelabs.com/news-releases/news-release-details/bioage-announces-positive-interim-phase-1-data-bge-102-novel https://ir.bioagelabs.com/news-releases/news-release-details/bioage-announces-positive-interim-phase-1-data-bge-102-novel"
X Link 2025-12-04T15:28Z [---] followers, [---] engagements

"$VIR Norgine HDV partnership EUR55m upfront up to EUR495m. Europe Australia NZ. Cash extended till 4Q2027. https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Grants-Norgine-Exclusive-Commercial-License-to-Chronic-Hepatitis-Delta-Treatment-Candidate-in-Europe-Australia--New-Zealand-Including-Global-Cost-Sharing-Agreement-for-Ongoing-ECLIPSE-Clinical-Development-Program/default.aspx"
X Link 2025-12-17T06:31Z [---] followers, [---] engagements

"$bmrn $fold $4.8b acquisition. Nice. https://www.biomarin.com/news/press-releases/biomarin-to-acquire-amicus-therapeutics-for-4-8-billion-expanding-position-as-a-leader-in-rare-diseases-accelerating-revenue-growth-and-strengthening-financial-outlook/ https://www.biomarin.com/news/press-releases/biomarin-to-acquire-amicus-therapeutics-for-4-8-billion-expanding-position-as-a-leader-in-rare-diseases-accelerating-revenue-growth-and-strengthening-financial-outlook/"
X Link 2025-12-19T12:58Z [---] followers, [---] engagements

"@BOSSTRADING0 Sanofi initial plan maybe just neuro $500-700m. Could have exercised after Parkinsons readout in July but choose to wait for Oct obesity. This indicates Sanofi is very interested in cardiometabolic. A fair price now could be $1.5b to $2b higher than $trml buyout. $vtyx"
X Link 2025-12-20T06:35Z [---] followers, [---] engagements

"$pepg Imminent data drop for 5mg/kg cohort for DM1. Guided 1Q26. Cruising up"
X Link 2026-01-02T15:11Z [---] followers, [---] engagements

"$VTYX Pull back into 7s together with #xbi high volume 10s options activity for Mar. On-going negotiations with Sanofi and/or others. $550m mkt cap only. $trml was bought by Novartis for $1.4b"
X Link 2026-01-06T00:50Z [---] followers, [----] engagements

"$prqr Data drop for AX-0810 Cohort [--] - 3mg/kg should be this month. This is a pivotal moment - first readout NTCP target engagement and safety. What to look out for - safety - bile acid levels profile TUDCA clearance - weight loss ()"
X Link 2026-01-06T01:17Z [---] followers, [----] engagements

"@RNAiAnalyst $ions $gsk #hbv No mention of functional cure rate in the press release. If it's very good they would have broadcast it. Their phase [--] only shows 10%.yeah higher than 1% SOC. $VIR has better results with Brii Bio. https://www.fiercebiotech.com/biotech/gsk-sees-hep-b-treatments-efficacy-drop-60-full-phase-2-readout-still-plans-phase-3 https://www.fiercebiotech.com/biotech/gsk-sees-hep-b-treatments-efficacy-drop-60-full-phase-2-readout-still-plans-phase-3"
X Link 2026-01-07T08:08Z [---] followers, [---] engagements

"$VTYX $14 per share $1.2b https://ir.ventyxbio.com/news-releases/news-release-details/lilly-acquire-ventyx-biosciences-advance-oral-therapies https://ir.ventyxbio.com/news-releases/news-release-details/lilly-acquire-ventyx-biosciences-advance-oral-therapies"
X Link 2026-01-07T23:46Z [---] followers, [---] engagements

"$BIOA $VTYX Strong move up since Ventyx taken out. NLRP3 is getting traction. Phase [--]. Still early. https://www.globenewswire.com/news-release/2026/01/12/3216965/0/en/BioAge-Announces-Additional-Positive-Interim-Phase-1-Data-for-BGE-102-a-Novel-Brain-Penetrant-NLRP3-Inhibitor-Demonstrating-Potential-for-Best-in-Class-hsCRP-Reduction-in-Participa.html_gl=1*1lez4ba*_up*MQ.*_ga*NDY2OTc5MTk5LjE3NjgyMjY1NjA.*_ga_ERWPGTJ5X8*czE3NjgyMjY1NjAkbzEkZzAkdDE3NjgyMjY1NjIkajU4JGwwJGgw"
X Link 2026-01-13T21:01Z [---] followers, [---] engagements

"$ARWR Redemplo approved in China https://www.globenewswire.com/news-release/2026/01/15/3219227/0/en/Press-Release-Myqorzo-and-Redemplo-approved-in-China.html https://www.globenewswire.com/news-release/2026/01/15/3219227/0/en/Press-Release-Myqorzo-and-Redemplo-approved-in-China.html"
X Link 2026-01-15T06:13Z [---] followers, [---] engagements

"$rapt $gsk And here it comes $2.2b deal. #JPM2026 was a deal maker stage. https://investors.rapt.com/news-releases/news-release-details/gsk-enters-agreement-acquire-rapt-therapeutics https://investors.rapt.com/news-releases/news-release-details/gsk-enters-agreement-acquire-rapt-therapeutics"
X Link 2026-01-20T07:52Z [---] followers, [----] engagements

"$rapt $gsk They also did a public offering in Oct [--] priced at $30 $250m. Negotiated from a position of strength. $ARWR $rapt $gsk And here it comes $2.2b deal. #JPM2026 was a deal maker stage. https://t.co/OZYx6HwFvq $rapt $gsk And here it comes $2.2b deal. #JPM2026 was a deal maker stage. https://t.co/OZYx6HwFvq"
X Link 2026-01-20T07:56Z [---] followers, [----] engagements

"$dawn Post #JPM2026 runs can only mean one thing. Increased revenues for lead drug in pLGG new ADCs going clinical $450m cash. Potential candidate after $rapt"
X Link 2026-01-20T15:53Z [---] followers, [---] engagements

"$prqr Privium and its other funds owns collectively 15.6%. Netherlands-based biotech fund. https://www.sec.gov/Archives/edgar/data/1795097/000110465926005130/xslSCHEDULE_13G_X01/primary_doc.xml https://www.sec.gov/Archives/edgar/data/1795097/000110465926005130/xslSCHEDULE_13G_X01/primary_doc.xml"
X Link 2026-01-23T14:52Z [---] followers, [----] engagements

"$ARWR Listen to what the market is saying.stock price is going to [---] this year. Pfizer paid $10b for Metsera that is the market cap of Arrow now. The rest is free"
X Link 2026-01-23T15:24Z [---] followers, [----] engagements

"$ABVX Wow.La Lettre doubled down. Call that journalist conviction. New reporting from La Lettre tonight: $ABVX Abivax justifies its silence to American analysts in the midst of a stock market surge While its stock price soared by 1600% in [----] the French biotech Abivax managed by Marc de Garidel recently engaged in an educational New reporting from La Lettre tonight: $ABVX Abivax justifies its silence to American analysts in the midst of a stock market surge While its stock price soared by 1600% in [----] the French biotech Abivax managed by Marc de Garidel recently engaged in an educational"
X Link 2026-01-26T09:42Z [---] followers, [----] engagements

"$xbi #xbi FED talk out of the way time to continue the uptrend. Now M&A talks can resume"
X Link 2026-01-29T00:14Z [---] followers, [---] engagements

"$IOVA 2/ Amtagvi - 1st full year revenue projected $250m to $300m. [----] patients so far treated. Past [--] quarters growth of 21.7% and 13% suggest manufacturing capacity problems are resolved. Sentiment still scarred by 1Q25 revenue miss"
X Link 2026-02-03T11:14Z [---] followers, [---] engagements

"$IOVA 3/ Higher real world ORR with earlier treatment drives more patients to TIL. Next-gen TIL products in pipeline combo trials may further increase uptake. Peak sales potential for melanoma $1b = 2k patients annually. Cases of melanoma in USA = 104k in [----] and rising"
X Link 2026-02-03T11:14Z [---] followers, [---] engagements

"$IOVA 4/ mNSCLC is 7x size of melanoma market. Lifileucel monotherapy lung data in Nov [--] is promising with 25.6% ORR and mDOR not reached after [----] months. If approved in [----] will be a game changer for Iovance revenue projections and valuation"
X Link 2026-02-03T11:14Z [---] followers, [---] engagements

"@yaireinhorn @igisci @RNAiAnalyst $MGX Metagenomi should reverse course and cut HemA trial. Tackle the bigger indications like Alzheimers'. Jill Banfield was co-founder of Metagenomi. Now Brian the other founder is out and it is LOST"
X Link 2025-11-21T07:45Z [---] followers, [---] engagements

"$sgmo We should know soon enough if this is a bidding war for their assets or Fabry. No way this trading is normal business. Either way shorts in heavy losses past [--] days. $sgmo No news up 25% shorts squeezed $sgmo No news up 25% shorts squeezed"
X Link 2026-01-31T10:53Z [---] followers, [---] engagements

"#gold #Silver #bitcoin #commodity What happened to the safe havens Thats what happen in the madness of crowds into these trades. #xbi downside should be limited. No leverage. No options. Hold equity. A few commercial names ripe for M&A"
X Link 2026-02-02T05:11Z [---] followers, [---] engagements

"#Currency China wants the world to hold renminbi they need the capital to boost property stocks and bonds. Its a matter of when. There is a lot money out there looking for an alternative to dollar. Xi calls for Chinas renminbi to attain global reserve currency status https://t.co/IxfQJp6Tky Xi calls for Chinas renminbi to attain global reserve currency status https://t.co/IxfQJp6Tky"
X Link 2026-02-02T10:54Z [---] followers, [---] engagements

"BREAKING: January CPI inflation falls to 2.4% below expectations of 2.5%. Core CPI inflation fell to 2.5% in-line with expectations of 2.5%. Core CPI inflation is now at its lowest level since March [----]. Odds of further interest rate cuts are back on the rise"
X Link 2026-02-13T13:32Z 1.4M followers, 310K engagements

"The Netherlands is about to commit financial self-destruction. Their parliament just passed a 36% tax on unrealized gains for investments. This will cause wealthy people to move to another tax jurisdiction. People will avoid launching a new business. Stock market investing will dry up. There is too much downside risk very little upside potential. The govt is confiscating most of the potential upside but leaving the investor with the downside risk. The politicians know this they have discussed it and they are concerned about it. But they did it anyways to close a short term budget gap of"
X Link 2026-02-12T23:53Z 1.7M followers, 746.9K engagements

"Commissioner @DrMakaryFDA must testify before the Health subcommittee on his terrible leadership of the Food & Drug Administration. Trust in safety & efficacy standards is collapsing"
X Link 2026-02-12T22:42Z 38.4K followers, 38.1K engagements

"💥BREAKING: 36% unrealized gains tax just passed in the Dutch House of Representatives"
X Link 2026-02-12T14:32Z 1.5M followers, 3.9M engagements

"$xbi #xbi Wall Street favorite trades.biotech is not one of them"
X Link 2026-02-06T01:28Z [---] followers, [---] engagements

"$mgx Nice strength in sea of red today. Of course. Cash is more than 2x mkt cap"
X Link 2026-02-05T16:10Z [---] followers, [---] engagements

"$IOVA 5/ TIL cell therapy could be for solid tumors what CAR-T is for blood cancers. Both are better treatments compared to chemo"
X Link 2026-02-03T11:14Z [---] followers, [---] engagements

"Xi calls for Chinas renminbi to attain global reserve currency status https://ft.trib.al/MB8Szj4 https://ft.trib.al/MB8Szj4"
X Link 2026-02-01T09:42Z 6.4M followers, 830.8K engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing